Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
September 16, 2021
According to the data of Yaozhi, Hengrui Medicine's application for the new indications of pyrrotinib maleate tablets was accepted by CDE. According to a press release issued by Hengrui Medicine, the new indication submitted by pirotinib may be: combined with trastuzumab plus docetaxel, preoperative treatment of early or locally advanced HER2-positive breast cancer.
The above is the Hengrui Medicine's application for the treatment of HER2-positive breast cancer with pyrrotinib has been accepted we have listed for you. You can submit the following form to obtain more industry information we provide for you.
You can visit our website or contact us, and we will provide the latest consultation and solutions
Send Inquiry
Most Popular
lastest New
Send Inquiry
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.